Cytek Biosciences Reports Q3 Revenue Growth and Provides 2026 Guidance
Cytek Biosciences (CTKB) reported third-quarter revenue of $53.2 million, representing a 2% increase compared to the same period last year. CEO Wenbin Jiang characterized the results as solid, reflecting steady performance within the company's current operations. Looking ahead, the company provided a revenue guidance range of $208 million to $211 million for the full year 2026. However, management announced that the rollout of its new business unit has been postponed from its original timeline to 2027, which may impact near-term growth expectations.
Tickers: $CTKB
Topics: earnings quarterly results revenue growth